Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
Dociparstat sodium
Jazz Pharmaceuticals Ireland Limited
Acute Myeloid Leukemia
1 trial -
Domvanalimab
Arcus Biosciences
Non Small Cell Lung Cancer
2 trials -
Domvanalimab
Arcus Biosciences
Head and Neck Squamous Cell Carcinoma
1 trial -
Domvanalimab
Arcus Biosciences
Advanced Non-Small Cell Lung Cancer
1 trial -
Donafenib + Envafolimab
Anhui Provincial Hospital
Hepatocellular Carcinoma
1 trial -
Dopacis 90 MBq/ml oplossing voor injectie
CERO THERAPEUTICS HOLDINGS, INC.
patients with newly discovered brain metastases (non-small cell lung cancer, breast cancer or melanoma) measuring more than 5 mm and explored on MRI
1 trial -
Dordaviprone (ONC201)
Jazz Pharmaceuticals Ireland Limited
Endometrial Cancer Recurrent
1 trial -
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab
Nektar Therapeutics UK Limited
Melanoma
1 trial -
Dostarlimab
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Ovarian Clear Cell Carcinoma
1 trial -
Doxorubicin Hydrochloride
Children's Hospital of Fudan University
Childhood Renal Cell Carcinoma
1 trial -
Doxorubicin liposome
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Doxycycline
United Therapeutics Europe Ltd
Advanced Malignant Neoplasm
1 trial -
Dragon Boat Training
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Drug: B10 L-BPA Injection
Heron Therapeutics
Head and Neck Cancer
1 trial -
Drug: GC4419
Galera Therapeutics
Head and Neck Cancer
1 trial -
Drug: Pembrolizumab
Hospital Authority, Hong Kong
Clear-cell Metastatic Renal Cell Carcinoma
1 trial -
Dupilumab
Regeneron UK Limited
Prostate Cancer
1 trial -
Dupilumab
Coherus Oncology
Metastatic Colorectal Cancer
1 trial -
Durvalumab
Syndax Pharmaceuticals
Unresectable Intrahepatic Cholangiocarcinoma
1 trial -
Durvalumab
United Therapeutics Europe Ltd
Stage IB Hepatocellular Carcinoma AJCC v8
1 trial -
Durvalumab + Oleclumab
MedImmune
Stage III Non-small Cell Lung Cancer
1 trial -
E7 TCR-T cells
Iovance Biotherapeutics B.V.
HPV-Associated Cervical Carcinoma
1 trial -
E7 TCR-T cells
Iovance Biotherapeutics B.V.
Cervical Cancer
1 trial -
E7080
Eisai Co.,
Solid Tumors
1 trial -
E7090
Eisai Co.,
Cholangiocarcinoma
1 trial -
E7386-G000-201
Eisai Co.,
colorectal cancer, melanoma, hepatocellular carcinoma
1 trial -
E7386-J081-102
Eisai Co.,
Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor
1 trial -
EBV-TCR-T (YT-E001) cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
EBV-specific T cells (EBV-CTLs)
Evidence Based Cataract Study Group
EBV-induced Lymphomas
1 trial -
EBVALLO
Pierre Fabre Medicament
EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)
1 trial -
EDGE-Lung
Gilead Sciences Pty Limited
Advanced Non-Small Cell Lung Cancer
1 trial -
EG-70 (phase 1)
Shanghai Antengene Corporation Limited
Superficial Bladder Cancer
1 trial -
EG-70-101
Shanghai Antengene Corporation Limited
Non-muscle invasive bladder cancer (NMIBC)
1 trial -
EGFR-TK Inhibitor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nonsmall Cell Lung Cancer
1 trial -
EIK1001-008
Eikon Therapeutics
Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
1 trial -
EIK1003-001
Eikon Therapeutics
Advance solid tumors
1 trial -
EIK1004 20mg Tablets, EIK1004 5mg Tablets
Eikon Therapeutics
Advanced solid tumors
1 trial -
EIK1004-001 (IMP1707-001)
Eikon Therapeutics
Advanced Solid Tumors
1 trial -
EIK1005
Eikon Therapeutics
Advanced Solid Tumors
1 trial -
EIK1005-002
Eikon Therapeutics
Advanced Solid Tumors
1 trial -
ELA-0121
Stemline Therapeutics B.V.
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer
1 trial -
ELI-002 7P
Elicio Therapeutics
Pancreatic Ductal Adenocarcinoma
1 trial -
ELVN-002-003
Enliven Therapeutics
Solid Tumors, Colorectal Cancer and Breast Cancer
1 trial -
EMB-01
Shanghai University of Traditional Chinese Medicine
Neoplasms
1 trial -
ENCORAFENIB , CETUXIMAB
The George Institute
Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.
1 trial -
ENGIC 01-COLOSOTO
CERO THERAPEUTICS HOLDINGS, INC.
colorectal cancer
1 trial -
ENHANCE
The George Institute
Intermediate risk prostate cancer
1 trial -
ENMD-2076
CASI Pharmaceuticals
Ovarian Cancer
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.